LXRX Lexicon Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LXRX

Price (delayed)

$2.16

Market cap

$959.46M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.07

Enterprise value

$942.06M

?
Relative Growth: Rel. Growth: 94
Relative Strength: Rel. Strength: 92
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 45

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes ...

Highlights
The company's gross profit has surged by 126% YoY and by 40% QoQ
LXRX's revenue has soared by 123% YoY and by 40% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.lexpharma.com
Peers: REGN RARE BMRN ILMN

Key stats

What are the main financial stats of LXRX

LXRX stock price

How has the Lexicon Pharmaceuticals stock price performed over time
Intraday
0.47%
1 week
10.77%
1 month
0%
1 year
194.24%
YTD
87.83%
QTD
38.46%

Financial performance

How have Lexicon Pharmaceuticals's revenue and profit performed over time
Revenue
$69.64M
Gross profit
$69.29M
Operating income
-$24.23M
Net income
-$26.09M
Gross margin
99.5%
Net margin
-37.5%
The company's gross profit has surged by 126% YoY and by 40% QoQ
LXRX's revenue has soared by 123% YoY and by 40% from the previous quarter
LXRX's operating margin has surged by 94% year-on-year and by 65% since the previous quarter
LXRX's net margin has surged by 93% year-on-year and by 63% since the previous quarter

Price vs fundamentals

How does LXRX's price correlate with its fundamentals

Growth

What is Lexicon Pharmaceuticals's growth rate over time

Valuation

What is Lexicon Pharmaceuticals stock price valuation
LXRX P/E details
P/E
N/A
P/B
4.51
P/S
12.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.53
The company's EPS has surged by 86% YoY and by 50% QoQ
Lexicon Pharmaceuticals's equity has surged by 89% QoQ and by 65% YoY
The P/B is 37% higher than the 5-year quarterly average of 3.3 and 29% higher than the last 4 quarters average of 3.5
LXRX's revenue has soared by 123% YoY and by 40% from the previous quarter
LXRX's price to sales (P/S) is 99% less than its 5-year quarterly average of 940.0 but 65% more than its last 4 quarters average of 7.5

Efficiency

How efficient is Lexicon Pharmaceuticals business performance
The company's return on sales has surged by 95% YoY and by 69% QoQ
The company's return on equity has surged by 82% YoY and by 56% QoQ
LXRX's ROA has soared by 79% YoY and by 46% QoQ
LXRX's ROIC has soared by 79% YoY and by 58% from the previous quarter

Dividends

What is LXRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LXRX.

Financial health

How did Lexicon Pharmaceuticals financials performed over time
LXRX's total liabilities has dropped by 62% year-on-year and by 15% since the previous quarter
The total assets has grown by 45% since the previous quarter but it has declined by 10% year-on-year
LXRX's debt is 76% smaller than its equity
Lexicon Pharmaceuticals's equity has surged by 89% QoQ and by 65% YoY
Lexicon Pharmaceuticals's debt to equity has shrunk by 71% YoY and by 52% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.